ZRG Partners Life Sciences Hiring Index Shows Modest Gains in 4th Quarter
ZRG Partners, Inc. announces the results of its fourth quarter Global Life Sciences Hiring Index
ZRG Partners, Inc. announces the results of its fourth quarter Global Life Sciences Hiring Index. Q4 reflects an overall gain in hiring, with Pharma activity over the long term reaching an all-time index high. Meanwhile R&D hiring took a hit dropping 15% from the previous quarter. The Asia Pacific Region saw significant hiring in Q4, more than 25%, with most being attributed to the Sales and Marketing function.
ZRG Managing Director David Fortier commented, “The results of this latest index correlate with the broader economy – inconsistencies across regions, sectors, and functions along with the continuation of a longer term trend of slow, steady, but uneven growth. The positive to take from these numbers is some robust hiring in selected functions within pharmaceuticals and a return of hiring in the commercial function indicating expectations of growth for some companies.”
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
